Approval · Notice of Compliance 36592 · 2025
MELVIZO: Notice of Compliance 36592
Issued November 7, 2025
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36592
- Date
- November 7, 2025
- Company
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product name change
- Canadian reference product
- LUCENTIS
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MELVIZO | 02525852 | Marketed |
Medicinal ingredients
- RANIBIZUMAB 10 MG per ML